Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes

Journal of Controlled Release

Volumn 183, Issue 1, 2014, Pages 146-153

  Mukthavaram, Rajesh ^a   Shi, Guixin ^a   Kesari, Santosh ^a,b   Simberg, Dmitri ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

Depletion; Lymphoma; RBC; Rituximab; Targeting

Indexed keywords

BIOCOMPATIBILITY; BLOOD; CELLS; CHEMICAL MODIFICATION; CYTOLOGY; DRUG DELIVERY; LIGANDS; ONCOLOGY;

DEPLETION; LYMPHOMA; RBC; RITUXIMAB; TARGETING;

ANTIBODIES;

ANTIBODY; CD45 ANTIBODY; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG; 1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE-N-METHOXY-POLY(ETHYLENE GLYCOL 2000); ANTINEOPLASTIC AGENT; DRUG CARRIER; LIGAND; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; PHOSPHATIDYLETHANOLAMINE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CIRCULATION; CLEARANCE; CONTROLLED STUDY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY; LEUKOCYTE; LIGAND PAINTED ERYTHROCYTE; LUNG; LYMPHOMA; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL; TARGET CELL; THERAPY EFFECT; ANIMAL; ANTIGEN ANTIBODY REACTION; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; CYTOLOGY; DRUG SCREENING; IMMUNOLOGY; LEUKAPHERESIS; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY REACTIONS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG CARRIERS; ERYTHROCYTES; FEMALE; HUMANS; LEUKOCYTE REDUCTION PROCEDURES; LEUKOCYTES; LIGANDS; MICE, INBRED BALB C; NEOPLASTIC CELLS, CIRCULATING; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84898782723     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2014.03.038     Document Type: Article

References (42)

1. J.M. Daley, A.A. Thomay, M.D. Connolly, J.S. Reichner, and J.E. Albina Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice J. Leukoc. Biol. 83 2008 64 70
2. M.R. Smith Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene 22 2003 7359 7368
3. P. Moreau et al. Rituximab in CD20 positive multiple myeloma Leukemia 21 2007 835 836 (Pubitemid 46444580)
4. T. van Meerten, R.S. van Rijn, S. Hol, A. Hagenbeek, and S.B. Ebeling Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity Clin. Cancer Res. 12 2006 4027 4035 (Pubitemid 44078090)
5. R. Bannerji et al. Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance J. Clin. Oncol. 21 2003 1466 1471 (Pubitemid 46594097)
6. H.H. Ruan, K.R. Scott, E. Bautista, and W.S. Ammons ING-1(heMAb), a monoclonal antibody to epithelial cell adhesion molecule, inhibits tumor metastases in a murine cancer model Neoplasia 5 2003 489 494 (Pubitemid 38045086)
7. M. Schmidt et al. Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer Ann. Oncol. 23 2012 2306 2313
8. M. Magnani et al. Erythrocyte-mediated delivery of drugs, peptides and modified oligonucleotides Gene Ther. 9 2002 749 751 (Pubitemid 34591480)
9. V.R. Muzykantov Drug delivery by red blood cells: vascular carriers designed by mother nature Expert Opin. Drug Deliv. 7 2010 403 427
10. S. Zaitsev et al. Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis Blood 108 2006 1895 1902 (Pubitemid 44403687)
11. V.R. Muzykantov, D.V. Sakharov, S.P. Domogatsky, N.V. Goncharov, and S.M. Danilov Directed targeting of immunoerythrocytes provides local protection of endothelial cells from damage by hydrogen peroxide Am. J. Pathol. 128 1987 276 285 (Pubitemid 17127152)
12. V.R. Muzykantov, D.V. Sakharov, M.D. Smirnov, S.P. Domogatsky, and G.P. Samokhin Targeting of enzyme immobilized on erythrocyte-membrane to collagen-coated surface FEBS Lett. 182 1985 62 66 (Pubitemid 15094693)
13. V.R. Muzykantov, D.V. Sakharov, M.D. Smirnov, G.P. Samokhin, and V.N. Smirnov Immunotargeting of erythrocyte-bound streptokinase provides local lysis of a fibrin clot Biochim. Biophys. Acta 884 1986 355 362 (Pubitemid 17188780)
14. G. Shi, R. Mukthavaram, S. Kesari, and D. Simberg Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo Advanced healthcare materials 3 2014 142 148
15. R.P. Taylor et al. In vivo binding and clearance of circulating antigen by bispecific heteropolymer-mediated binding to primate erythrocyte complement receptor J. Immunol. 148 1992 2462 2468
16. J.H. Powers et al. Complement-independent binding of microorganisms to primate erythrocytes in-vitro by cross-linked monoclonal-antibodies via complement receptor-1 Infect. Immun. 63 1995 1329 1335
17. R.P. Taylor et al. Use of heteropolymeric monoclonal-antibodies to attach antigens to the C3b receptor of human erythrocytes - a potential therapeutic treatment Proc. Natl. Acad. Sci. U. S. A. 88 1991 3305 3309 (Pubitemid 21916609)
18. G. Shi, R. Mukthavaram, S. Kesari, and D. Simberg Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo Advanced healthcare materials 3 2014 142 148
19. M. Cristofanilli et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer N. Engl. J. Med. 351 2004 781 791 (Pubitemid 39095313)
20. V. Choesmel et al. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance Breast Cancer Res. 6 2004 R556 R570
21. M.L. Thomas The leukocyte common antigen family Annu. Rev. Immunol. 7 1989 339 369 (Pubitemid 19138017)
22. D.L. Kooyman et al. In-vivo transfer of Gpi-linked complement restriction factors from erythrocytes to the endothelium Science 269 1995 89 92
23. M.Y. Kim et al. Tumor self-seeding by circulating cancer cells Cell 139 2009 1315 1326
24. M. Yu, S. Stott, M. Toner, S. Maheswaran, and D.A. Haber Circulating tumor cells: approaches to isolation and characterization J. Cell Biol. 192 2011 373 382
25. H.J. Jeon, C.W. Kim, T. Yoshino, and T. Akagi Establishment and characterization of a mantle cell lymphoma cell line Br. J. Haematol. 102 1998 1323 1326 (Pubitemid 28435219)
26. F.S. Hodi et al. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 2010 711 723
27. C.M.J. Hu, R.H. Fang, J. Copp, B.T. Luk, and L.F. Zhang A biomimetic nanosponge that absorbs pore-forming toxins Nat. Nanotechnol. 8 2013 336 340
28. F. Geissmann, S. Jung, and D.R. Littman Blood monocytes consist of two principal subsets with distinct migratory properties Immunity 19 2003 71 82 (Pubitemid 36859902)
29. J.C. Ra et al. Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans Stem Cells Dev. 20 2011 1297 1308
30. V. Annese et al. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study Am. J. Gastroenterol. 100 2005 1370 1375 (Pubitemid 40904364)
31. M. Castro et al. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease J. Pediatr. Gastroenterol. Nutr. 44 2007 423 426 (Pubitemid 46573223)
32. R.J. Brentjens et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia Sci. Transl. Med. 5 2013 (177ra138)
33. A. Mackensen et al. Phase I study of adoptive T-cell therapy using antigen-specific CD8 + T cells for the treatment of patients with metastatic melanoma J. Clin. Oncol. 24 2006 5060 5069 (Pubitemid 46631410)
34. S.A. Rosenberg, and M.E. Dudley Adoptive cell therapy for the treatment of patients with metastatic melanoma Curr. Opin. Immunol. 21 2009 233 240
35. J. Golay et al. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59 Blood 98 2001 3383 3389
36. R.I. Fisher et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N. Engl. J. Med. 328 1993 1002 1006 (Pubitemid 23095683)
37. G.I. Bell Models for the specific adhesion of cells to cells Science 200 1978 618 627
38. V. Terpstra, and T.J. van Berkel Scavenger receptors on liver Kupffer cells mediate the in vivo uptake of oxidatively damaged red blood cells in mice Blood 95 2000 2157 2163 (Pubitemid 30151660)
39. J. Yan et al. Critical role of Kupffer cell CR3 (CD11b/CD18) in the clearance of IgM-opsonized erythrocytes or soluble beta-glucan Immunopharmacology 46 2000 39 54 (Pubitemid 30026201)
40. V.P. Torchilin, A.N. Lukyanov, Z. Gao, and B. Papahadjopoulos-Sternberg Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs Proc. Natl. Acad. Sci. U. S. A. 100 2003 6039 6044 (Pubitemid 36576927)
41. P.R. Hinton et al. Engineered human IgG antibodies with longer serum half-lives in primates J. Biol. Chem. 279 2004 6213 6216 (Pubitemid 38248752)
42. P. Vieira, and K. Rajewsky The half-lives of serum immunoglobulins in adult mice Eur. J. Immunol. 18 1988 313 316 (Pubitemid 18078861)